JFDA, WHO delegation talk drug regulation cooperation

Amman: Director General of Jordan Food and Drug Administration (JFDA), Dr. Nizar Mhaidat, said the administration continues efforts to reach an "advanced" level in regulating drugs and finally certify it as an internationally accredited regulatory body, under the World Health Organization (WHO)'s program for regulatory systems strengthening (RSS). During a meeting with a WHO mission of experts on a follow-up visit within the RSS program's framework, Mhaidat noted the trip's importance to follow up on the progress made in implementing the recommendations made during previous visits to the JFDA and build on related development and improvement, in accordance with a specific timetable. Mhaidat added that this process aligns with the JFDA's strategy to apply the "highest" international standards to ensure drug quality, safety and efficacy and its keenness to support the Kingdom's pharmaceutical industry sector and enhance its competitiveness, in line with outcomes of the Economic Modernization Vision that was la unched under Royal directives. Meanwhile, WHO Representative to Jordan, Jamela Al-Raiby, praised the JFDA's efforts in achieving "continuous" development and implementation of the organization's recommendations. In this regard, Al-Raiby referred to joint action to develop performance of the Kingdom's entire drug regulation system, which would reflect "positively" on the JFDA's monitoring and regulatory role that would qualify it to reach the Maturity Level 3 or 4 for regulating locally produced and imported drugs. Source: Jordan News Agency